0
0
MELBOURNE, Australia — In a breakthrough for gynecological oncology, researchers at Monash University have successfully demonstrated a “world-first” application of stabilized hyaluronic acid (sHA) gel to protect healthy organs during internal radiation therapy. The pilot study, published in the Journal of Medical Radiation Sciences, marks a significant step toward reducing the debilitating side effects often associated with cervical and vaginal cancer treatments.
While hyaluronic acid is a household name in skincare for its hydrating properties, its role in oncology is purely mechanical. By acting as a “liquid cushion,” the gel creates physical distance between a tumor and the rectum, allowing doctors to deliver higher, more effective doses of radiation to the cancer while sparing healthy tissue from collateral damage.
The Challenge of Proximity in Brachytherapy
For patients with gynecological cancers, brachytherapy—a form of internal radiation where a radioactive source is placed inside or near the tumor—is a gold standard of care. However, the proximity of the rectum to the cervix and vagina presents a persistent anatomical challenge.
“The goal of radiation is always a delicate balancing act,” says Dr. Carminia Lapuz, lead researcher from Monash University’s School of Clinical Sciences. “We want to deliver a high enough dose to eradicate the tumor, but we are limited by how much radiation the surrounding healthy organs can tolerate. If the rectum is too close, we may have to under-dose the tumor or risk long-term bowel complications.”
Chronic radiation proctitis—inflammation of the rectal lining—can lead to bleeding, pain, and urgency, significantly impacting a patient’s quality of life following successful cancer treatment.
A “Liquid Shield” for Women’s Health
The Australian team recruited 12 patients to test the feasibility of injecting a stabilized hyaluronic acid (sHA) gel spacer. This technique is not entirely new to medicine; sHA is already approved by regulatory bodies like Australia’s Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA) for use in prostate cancer treatments to separate the prostate from the rectum.
This study, however, represents the first time the material has been rigorously tested in a gynecological context.
Key Findings from the Study:
-
Safety and Feasibility: The procedure was deemed safe for all 12 participants, with no adverse complications related to the gel injection.
-
Visibility: The gel was clearly visible on MRI scans, allowing clinicians to verify its position and ensure the “spacer” remained where it was needed throughout the treatment.
-
Anatomical Success: The gel successfully increased the distance between the tumor and the rectum in every patient involved in the trial.
-
Patient Comfort: Despite the invasive nature of the injection, patients reported no additional discomfort or pain associated with the spacer.
The gel is biocompatible and naturally dissolves in the body over several months, meaning no follow-up surgery is required to remove it once the radiation course is complete.
Expert Perspectives: Moving Toward Equity in Cancer Care
Medical professionals not involved in the study suggest that this could be a turning point for “precision protection” in women’s oncology.
“Historically, many of the technological advancements in radiation ‘spacing’ have focused on prostate cancer,” notes Dr. Sarah Thompson, a radiation oncologist specializing in gynecological malignancies (who was not affiliated with the Monash study). “Applying this to gynecological cancers is a vital move toward equity. It addresses the unique anatomical challenges women face and offers a potential path to reducing the long-term ‘hidden’ side effects of cancer survivorship.”
Dr. Lapuz echoed this sentiment, stating that by increasing this distance, clinicians hope to pave the way for “greater equity in cancer care,” ensuring women have access to the same protective technologies that have been standard for men’s pelvic cancers for years.
Limitations and Future Outlook
While the results are promising, the study was small, focusing on 12 patients primarily to prove that the procedure is feasible (can be done) and safe (doesn’t cause immediate harm).
What the study didn’t measure:
-
Long-term Side Effects: Because the study was focused on the procedure itself, researchers did not yet track whether these patients experienced fewer bowel issues five or ten years down the line.
-
Survival Rates: The study was not designed to measure if the gel leads to higher cure rates, though the ability to deliver higher radiation doses suggests a strong potential for better outcomes.
The next phase of research will likely involve larger, multi-center trials to quantify exactly how much the rectal radiation dose is reduced and how that translates to the day-to-day health of survivors.
What This Means for Patients
For those currently diagnosed with or undergoing treatment for gynecological cancers, this research offers a glimpse into the future of personalized oncology. While sHA spacers for gynecological use are not yet the universal standard of care, their success in this trial suggests they may soon be integrated into clinical practice.
Patients are encouraged to discuss “organ-at-risk” sparing techniques with their radiation oncology team. While traditional methods like packing the vaginal vault with gauze are still common, the use of injectable gels represents a move toward more stable and precise protection.
Reference Section
- https://www.ndtv.com/health/hyaluronic-acid-may-be-beneficial-in-treating-some-cancers-study-10780167
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
